A New Business Model For Deprioritized Clinical Trials
Executive Summary
While the pharmaceutical industry faces many issues, a lack of potential assets is not one of them. A structured approach to developing those products, which may have been deprioritized because of company resources or do not promise the ROI needed by external investors, is being explored to the benefit of all parties.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.